| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/26/2009 | US7538091 D-retro-inverso amino acid sequence transporter peptide conjugated to nucleic acid biological effector; translocation across the membrane of pancreatic B-cells |
| 05/26/2009 | US7538089 Anti-inflammatory compounds and uses thereof |
| 05/26/2009 | US7537924 Modified herpes simplex viral particle for targeting and destroying tumor cells |
| 05/26/2009 | US7537899 Defects in periaxin associated with myelinopathies |
| 05/26/2009 | US7537887 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 05/26/2009 | US7537005 Dose dispensing system and apparatus |
| 05/26/2009 | CA2494165C Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate |
| 05/26/2009 | CA2474373C N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substituent on the methyl useful as bradykinin antagonists |
| 05/26/2009 | CA2463264C 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists |
| 05/26/2009 | CA2459432C Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
| 05/26/2009 | CA2436668C Novel succinate salt of o-desmethyl-venlafaxine |
| 05/26/2009 | CA2384504C Use of retigabin for treating neuropathic pain |
| 05/26/2009 | CA2376949C Heterocyclic aminopyrrolidine derivatives as melatonergic agents |
| 05/26/2009 | CA2355077C Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
| 05/26/2009 | CA2344058C Diaminopropionic acid derivatives |
| 05/26/2009 | CA2337041C Aminomethylcarboxylic acid derivatives |
| 05/26/2009 | CA2301860C Chemical and pharmacological standardization of herbal extracts |
| 05/26/2009 | CA2279498C The use of levobupivacaine in paediatric surgery |
| 05/22/2009 | WO2009064747A2 4(-3-(-2-(phenyl) morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl) benzenesulfon amide derivatives and related compounds as modulators of ion channels for the treatment of pain |
| 05/22/2009 | WO2009064684A1 Substituted heterocyclic ethers and their use in cns disorders |
| 05/22/2009 | WO2009064422A2 Hepatocyte growth factor pathway activators in fibrotic connective tissue diseases |
| 05/22/2009 | WO2009064418A1 Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
| 05/22/2009 | WO2009064151A1 Method of obtaining a dry extract of galphimia glauca, pharmaceutical compositions comprising said extract and use of the compositions to treat anxiety |
| 05/22/2009 | WO2009064004A1 Citrulline-containing drink |
| 05/22/2009 | WO2009063993A1 Fused pyridine derivative and use thereof |
| 05/22/2009 | WO2009063990A1 Benzazepinone compound |
| 05/22/2009 | WO2009063953A1 Phenylpyrazole derivatives |
| 05/22/2009 | WO2009063872A1 Pseudoginseng extract |
| 05/22/2009 | WO2009063821A1 Heteroaryloxy quinazoline derivative |
| 05/22/2009 | WO2009063459A2 Synthetic peptide copolymers for treatment of neurodevelopmental disorders |
| 05/22/2009 | WO2009063171A1 Novel rotigotine salts |
| 05/22/2009 | WO2009063170A1 Preparation of crystalline rotigotine base |
| 05/22/2009 | WO2009062987A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use |
| 05/22/2009 | WO2009062949A1 New polymorphic forms of n-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide |
| 05/22/2009 | WO2009062930A1 Heterocyclic derivatives |
| 05/22/2009 | WO2009062750A2 Active soluble post-translationally modified neuregulin isoforms |
| 05/22/2009 | WO2009062517A1 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity |
| 05/22/2009 | WO2009062431A1 A method for smoking cessation |
| 05/22/2009 | WO2009062391A1 Memantine protects inflammation-related degeneration of dopamine neurons through inhibition of over-activated microglia and release of neurotrophic factors from astroglia |
| 05/22/2009 | WO2009062374A1 The pharmaceutical use of liquiritigenin for preparing medicine for treating neurodegenerative diseases |
| 05/22/2009 | WO2009062319A1 Indole compounds and methods for treating visceral pain |
| 05/22/2009 | WO2009062318A1 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity |
| 05/22/2009 | WO2009062260A1 Therapy for multiple sclerosis |
| 05/22/2009 | WO2009062258A1 N-containing heterocyclic compounds |
| 05/22/2009 | WO2009043507A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009043468A3 Use of corticotropin-releasing factor as a therapeutic agent |
| 05/22/2009 | WO2009040552A3 Substituted imidazo (2, 1-b) -1, 3, 4-thiazole compounds, their pharmaceutical compositions and uses thereof |
| 05/22/2009 | WO2009040087A3 Therapeutic use of peptide yglf and combination with kvlpvpq |
| 05/22/2009 | WO2009040073A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009040032A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009040025A3 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent |
| 05/22/2009 | WO2009039969A3 Use of a vla-4 inhibitor tetrapeptide, alone or in combination with bpp-b, as a therapeutic agent |
| 05/22/2009 | WO2009034028A3 Novel compounds |
| 05/22/2009 | WO2009033822A3 Use of a combination of a cathepsin g fragment and teprotide as a therapeutic agent |
| 05/22/2009 | WO2009033812A3 Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent |
| 05/22/2009 | WO2009033800A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009033771A3 Use of a peptide as a therapeutic agent |
| 05/22/2009 | WO2009033736A3 Use of met-enkephalin as a therapeutic agent |
| 05/22/2009 | WO2009033735A3 Use of melanin concentrating hormone and met-enkephalin as therapeutic agents |
| 05/22/2009 | WO2009033669A3 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent |
| 05/22/2009 | WO2008118403A3 Method of using a pkc inhibitor to reverse prefrontal cortical declines |
| 05/22/2009 | WO2008100450A3 Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury |
| 05/22/2009 | WO2008100449A3 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury |
| 05/22/2009 | WO2008092591A9 Use of guanidinoacetic acid (salts) combined with betaine and/or choline for producing a health-promoting agent |
| 05/22/2009 | WO2008077557A8 8-ethinylxanthine derivatives as selective a2a receptor antagonists |
| 05/22/2009 | CA2706556A1 Citrulline-containing beverage |
| 05/22/2009 | CA2705916A1 Benzazepinone compound |
| 05/22/2009 | CA2705835A1 Indole compounds and methods for treating visceral pain |
| 05/22/2009 | CA2705833A1 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity |
| 05/22/2009 | CA2705513A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their medical use |
| 05/22/2009 | CA2705508A1 New polymorphic forms of n-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide |
| 05/22/2009 | CA2705502A1 Phenylpyrazole derivatives |
| 05/22/2009 | CA2705370A1 Heteroaryloxy quinazoline derivatives |
| 05/22/2009 | CA2705336A1 Heterocyclic derivatives as modulators of ion channels |
| 05/22/2009 | CA2705328A1 Active soluble post-translationally modified neuregulin isoforms |
| 05/22/2009 | CA2705163A1 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity |
| 05/22/2009 | CA2704436A1 Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| 05/22/2009 | CA2703901A1 Heterocyclic derivatives |
| 05/22/2009 | CA2703600A1 N-containing heterocyclic compounds |
| 05/21/2009 | US20090131645 used to control the interaction of particular cell types with their external environment; for chronic pain; reduced side effects, long-lasting actions that do not require frequent injections or long-term catheterization; does not lead to tolerance and associated dependence |
| 05/21/2009 | US20090131535 Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors |
| 05/21/2009 | US20090131526 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131525 Administering L-lysine-d-amphetamine or salts |
| 05/21/2009 | US20090131510 Compounds with activity at estrogen receptors |
| 05/21/2009 | US20090131509 Aminoacid Derivatives Containing a Disulfanyl Group in the form of Mixed Disulfanyl and Aminopeptidase N Inhibitors |
| 05/21/2009 | US20090131508 Use of 2-Oxo-1-Pyrrolidone Derivatives for the Preparation of a Drug |
| 05/21/2009 | US20090131507 e.g. [2-(1-(Benzenesulfonyl)-1H-indol-3-yloxy)ethyl]dimethylamine; serotonin, melatonin receptor ligand; antidepressant, anxiolytic agent; cognition activator; psychosis, schizophrenia, migraine headache, drug addiction, convulsions, osteoporosis, ischemic stroke, Alzheimer's, Parkinson's diseases |
| 05/21/2009 | US20090131505 chronic lymphocytic leukemia or acute lymphoblastic leukemia; use of specific compound (1R)-cyclopropanecarboxylic acid {2-[2-carbamoyl-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-7-chloro-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide |
| 05/21/2009 | US20090131501 Alzheimer's disease; administering orally (+) phenserine; phenserine tartrate; racemic or enantiomerically pure; not toxic in a wide range of dosages |
| 05/21/2009 | US20090131498 Enantioselective Synthesis of Merrilactone and Its Analogs |
| 05/21/2009 | US20090131497 Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments |
| 05/21/2009 | US20090131492 Indole derivatives as CFTR modulators |
| 05/21/2009 | US20090131482 Methyl-benzimidazole derivatives |
| 05/21/2009 | US20090131480 Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia |
| 05/21/2009 | US20090131477 New use of iloperidone |
| 05/21/2009 | US20090131476 Abuse-resistant amphetamine prodrugs |
| 05/21/2009 | US20090131459 2-Thioxanthine Derivatives Acting as MPO-Inhibitors |
| 05/21/2009 | US20090131456 Caspase inhibitors and uses thereof |
| 05/21/2009 | US20090131452 4-[5-(3-Difluoromethoxy-benzenesulfonylamino)-2-methoxy-phenyl]- piperazine-1-carboxylic acid tert-butyl ester; nervous system disorders, particularly the central nervous system; obesity; cogition activators; Alzheimer's disease; drug abuse, drug dependence; schizophrenia; bioavailability; stability |
| 05/21/2009 | US20090131440 Heterocyclic derivatives as modulators of ion channels |